BNP Paribas Arbitrage SA Boosts Stake in Inogen, Inc (INGN)

BNP Paribas Arbitrage SA lifted its holdings in Inogen, Inc (NASDAQ:INGN) by 63.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,052 shares of the medical technology company’s stock after buying an additional 1,961 shares during the period. BNP Paribas Arbitrage SA’s holdings in Inogen were worth $482,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of INGN. BlackRock Inc. increased its holdings in shares of Inogen by 145,976.1% in the 1st quarter. BlackRock Inc. now owns 2,110,800 shares of the medical technology company’s stock worth $163,711,000 after buying an additional 2,109,355 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Inogen by 166.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 196,886 shares of the medical technology company’s stock worth $18,786,000 after buying an additional 122,913 shares during the last quarter. MARSHALL WACE ASIA Ltd bought a new stake in shares of Inogen in the 1st quarter worth about $9,139,000. Marshall Wace North America L.P. bought a new stake in shares of Inogen in the 1st quarter worth about $9,139,000. Finally, FMR LLC increased its holdings in shares of Inogen by 56.2% in the 1st quarter. FMR LLC now owns 324,200 shares of the medical technology company’s stock worth $25,145,000 after buying an additional 116,600 shares during the last quarter.

A number of analysts have recently weighed in on the stock. Needham & Company LLC reduced their target price on shares of Inogen from $108.00 to $96.00 and set a “strong-buy” rating on the stock in a report on Thursday, June 8th. BidaskClub downgraded shares of Inogen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Zacks Investment Research downgraded shares of Inogen from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 8th. Piper Jaffray Companies restated a “hold” rating and issued a $90.00 target price on shares of Inogen in a report on Tuesday. Finally, J P Morgan Chase & Co boosted their target price on shares of Inogen to $102.00 and gave the stock an “overweight” rating in a report on Monday, June 26th. Four equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $91.33.

ILLEGAL ACTIVITY WARNING: This report was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://www.chaffeybreeze.com/2017/09/15/bnp-paribas-arbitrage-sa-boosts-stake-in-inogen-inc-ingn.html.

Inogen, Inc (NASDAQ INGN) opened at 103.65 on Friday. Inogen, Inc has a one year low of $50.24 and a one year high of $104.88. The company has a market capitalization of $2.15 billion, a P/E ratio of 89.97 and a beta of 1.02. The company’s 50-day moving average is $95.76 and its 200 day moving average is $87.16.

Inogen (NASDAQ:INGN) last released its quarterly earnings data on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.28 by $0.10. Inogen had a net margin of 10.36% and a return on equity of 12.45%. The firm had revenue of $64.10 million during the quarter, compared to analysts’ expectations of $59.99 million. During the same period last year, the business earned $0.25 earnings per share. Inogen’s revenue was up 17.4% compared to the same quarter last year. On average, equities analysts anticipate that Inogen, Inc will post $1.21 earnings per share for the current year.

In related news, EVP Matt Scribner sold 2,500 shares of the firm’s stock in a transaction dated Tuesday, July 18th. The shares were sold at an average price of $94.21, for a total transaction of $235,525.00. Following the completion of the sale, the executive vice president now directly owns 4,833 shares in the company, valued at $455,316.93. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Raymond Huggenberger sold 14,000 shares of the firm’s stock in a transaction dated Friday, July 14th. The stock was sold at an average price of $92.96, for a total transaction of $1,301,440.00. Following the sale, the director now owns 7,808 shares of the company’s stock, valued at $725,831.68. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 44,667 shares of company stock valued at $4,170,776. 5.31% of the stock is owned by company insiders.

Inogen Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply